India decries US 'arm twisting' tactics over Nexavar compulsory licence
This article was originally published in Scrip
Recent comments by the US deputy under secretary of commerce for intellectual property and deputy director of the US Patent and Trademark Office (PTO) Teresa Stanek Rea expressing "dismay and surprise" over India's granting of a compulsory licence for Bayer's anticancer Nexavar (sorafenib tosylate), and her suggestion that approaching the World Trade Organization (WTO) could be one of the "tools in the toolkit" to remedy it, have been strongly criticised in India as US pressure tactics driven by "domestic compulsions".
You may also be interested in...
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.
Alembic says it is 'comfortably placed' in terms of inventories and is seeing improving API supplies from China. The only area of some concern is outbound logistics against a backdrop of flights being halted and population lock-downs.